FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to psychiatry, and can be used to prevent the onset of akathisia in patients with schizophrenia on selection of an antipsychotic drug. The age of manifestation of schizophrenia, the duration of the disease, the overall score on the PANSS scale, the Tanner index and the waist circumference are determined. At the simultaneous value of the combination of indicators of: 1 – age of manifestation of schizophrenia of 19 years and earlier and the duration of the disease of 24 years and more; 2 – age of manifestation of schizophrenia of 19 and earlier and the duration of the disease of 4 years and less; 3 – age of manifestation of schizophrenia of 20 years and later, the Tanner index of 76 and greater; 4 – age of manifestation of schizophrenia of 20 years to 43 years, the Tanner index of 76 and greater, the overall score on the PANSS scale of 92 and the waist circumference from 77 cm to 102 cm, a high probability of development of akathisia is predicted and drugs with a low risk of onset of akathisia are prescribed.
EFFECT: ensures prediction of the probability of akathisia for supporting the medical decision on selection of antipsychotic therapy in patients with schizophrenia by evaluating a set of the most significant indicators.
1 cl, 1 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTING DEVELOPMENT OF VISCERAL OBESITY IN PATIENTS WITH SCHIZOPHRENIA RECEIVING QUETIAPINE THERAPY | 2017 |
|
RU2659638C1 |
METHOD FOR PREDICTION OF METABOLIC SYNDROME DEVELOPMENT IN SCHIZOPHRENIC PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY | 2018 |
|
RU2703424C1 |
USE OF METHYL ETHER OF N-CAPROYL-L-PROLYL-L-TYROSINE (DILEPT) AS AGENT WITH PSYCHOSTIMULANT ACTIVITY | 2015 |
|
RU2593886C1 |
METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN SCHIZOPHRENIC PATIENTS | 2014 |
|
RU2546021C1 |
METHOD FOR PREDICTING THE EFFICIENCY OF TREATING PATIENTS WITH SCHIZOPHRENIA WITH ATYPICAL NEUROLEPTIC QUETIAPIN (SEROQUEL) | 2005 |
|
RU2289137C1 |
METHOD FOR PREDICTING THE DEGREE OF RISK OF EXTRAPYRAMID SIDE EFFECTS DURING THE BACKGROUND OF HALOPERIDOL THERAPY IN PATIENTS WITH SCHIZOPHRENIC SPECTRUM DISORDERS | 2021 |
|
RU2771180C1 |
METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF PATIENTS WITH SCHIZOPHRENIA | 2021 |
|
RU2775440C1 |
METHOD OF PREDICTING RISK OF DEVELOPING HYPERPROLACTINEMIA IN WOMEN WITH SCHIZOPHRENIA TAKING ANTIPSYCHOTIC THERAPY | 2023 |
|
RU2810398C1 |
METHOD OF EFFICIENCY FORECAST FOR RESIDUAL SHIZOPHRENIA TREATMENT BY ATYPICAL NEUROLEPTIC QUETIAPINE | 2007 |
|
RU2349918C1 |
METHOD FOR PREDICTION OF CLINICAL COURSE OF SCHIZOPHRENIA IN MEN WITH PAROXYSMAL ENDOGENOUS PSYCHOSES MANIFESTING AT AGE FROM 18 TO 25 YEARS | 2018 |
|
RU2685549C1 |
Authors
Dates
2021-10-04—Published
2021-04-07—Filed